CytoMed Therapeutics and Hangzhou CNK Therapeutics Enter Memorandum of Understanding (MOU)
Wednesday, August 16, 2023
CytoMed Therapeutics has announced its recent collaboration with Hangzhou CNK Therapeutics, marked by the signing of a Memorandum of Understanding (MOU).
This collaboration is aimed at bolstering the in vivo longevity of allogeneic CAR γδ T cells. Notably, this MOU represents the first of multiple cooperative endeavours in North Asia.
With this agreement, CytoMed gains access to CNK's PiggyBac technology, a non-viral gene editing method, enabling the permanent integration of the Chimeric Antigen Receptor (CAR) gene into its gamma delta (γδ) T cells.
The MOU comes with a one-year duration, subject to renewal, and contingent upon a definitive agreement and customary closing conditions. Additionally, the potential for a joint venture to conduct clinical trials in China remains on the horizon.
These strategic collaborations significantly enhance CytoMed's technological prowess, propelling closer to the aspiration of advancing cost-effective, "off-the-shelf" allogeneic cellular immunotherapies to address a wide range of cancer types.
